Recombinant Human Acidic Fibroblast Growth Factor (aFGF/FGF1)

Recombinant (E. coli)

Lyophilizate, sterile-filtered

Cat.No.     RP1003                       10 μg                  store at -20 ℃

Synonyms :  Fibroblast Growth Factor-acidic, FGF-1, HBGF-1, ECGF-beta, FGF-a

Description:  Human Recombinant Fibroblast Growth Factor-1 (FGF-1) produced in E.coli is a single, non-glycosylated, polypeptide chain containing 155 amino acids and having a molecular mass of 17460 Dalton.

Source:        Escherichia coli.

Purity:         Greater than 95.0% as determined by SDS-PAGE.           

Endotoxin Level: Endotoxin level is less than 0.1 ng per μg (1EU/μg) as determined by the LAL method.

Biological Activity: The ED50, calculated by the dose-dependent proliferation of mouse BALB/c 3T3 cells is <1.0 ng/ml, corresponding to a Specific Activity of 1 x 1,000,000 IU/mg.

Amino acid sequence:

MAEGEITTFTALTEKFNLPPGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQLSAESVGEVYIKSTETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEKNWFVGLKKNGSCKRGPRTHYGQKAILFLPLPVSSD

Formulation & Storage: It was lyophilized from sterile 10 mM sodium phosphate ( pH 7.4) and we recommend that the powder be reconstituted in sterile 10 mW-cm H₂O. Upon reconstitution aFGF should be stored at 4°C. For long-term storage at -20°C, it is recommended to add a carrier protein (0.1% HSA or BSA). Freeze-thaw cycles should be avoided.

Usage:  The product is for research only and may not be allowed for usage as drugs, agricultural or pesticidal products, food additives or household chemicals.

Biowit Technologies Ltd. is a high-tech company specialized in providing R&D services and related products in the biological field. As a technology-driven and customer-focused company, BioWit provides a broad and integrated service and product portfolio including molecular biology, virus packaging (e.g., adenovirus, AAV, lentivirus, retrovirus and baculovirus), protein expression, cell biology, stem cells and transgenic models. One of the milestones achieved by Biowit is its recent sucess in the development of a series of serum-containing media as well as serum-free or animal -free media for stem cell culture, which are tailored for clinical applications. The core technology team members have engaged in research and development for many years in world-famous academic institutions or prestigious drug companies. Biowit has established collaboration with international prestigious research institutions. The worldwide collaboration enables Biowit to timely renew its biotechnologies (http://www.biowit.com).